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Abstract 
Objective: To assess the clinical importance of on-treatment function testing of platelets in 
patients on aspirin after catheter-based vascular interventions.  
Materials and Methods: In 109 patients with symptomatic peripheral arterial disease (PAD) 
of the lower limbs, platelet function testing (ADP-, collagen- and epinephrine-induced 
aggregation using light transmission aggregometry) was performed before and at multiple 
time points up to one year after a percutaneous angioplasty. Using univariate mixture models 
and Box-Cox transformation to ensure normally distributed individual variances we 
investigated if an intraindividual variability exists and if it has a consequence for clinical 
outcome.  
Results: Response to aspirin as measured by platelet aggregometry varies considerably over 
time in most patients. However, the intraindividual variance over time was neither 
significantly correlated with restenosis/reocclusion after one year nor with adverse long-term 
outcome (occurrence of death for cardiovascular cause, stroke, or myocardial infarction in up 
to eight years follow-up).  
Conclusions: Response to aspirin does not seem to have a role in determining long-term 
outcome in patients with symptomatic PAD. The fact that testing of platelet function at only 
one time point has reduced significance may have implications for all clinical settings in 
which aspirin is used for the prevention of thromboembolic events. 
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Introduction 
Aspirin (acetylsalicylic acid; ASA) is one of the most important drugs used for the prevention 
of thromboembolic vascular events. A highly variable interindividual platelet response to the 
treatment with aspirin has been reported.1 “Aspirin resistance” is defined differently by 
different groups. Clinically, “aspirin resistance” or hyporesponsiveness occurs in patients 
who, although being on therapeutic doses of aspirin, develop thromboembolic cardiovascular 
events.2 Others, however, have supported not including “thromboembolic events while on 
aspirin” as a clinical definition for aspirin resistance as only about one fourth of all vascular 
complications can be prevented by any one pharmacological therapy alone.3 
Biochemical assessment of platelet function may detect hypo- or non-response of platelets to 
aspirin therapy. However, to date, it is not clear which of several available laboratory methods 
has the best reliability and, in particular, the highest predictability for clinical events.4 A 
recent meta-analysis of 20 studies using different aggregation tests to assess individual 
platelet response to aspirin demonstrated an elevated cardiovascular risk associated with 
aspirin resistance.5 Therefore, although the clinical importance of non-responsiveness is not 
yet fully understood, there is evidence for its clinical relevance. Furthermore, in patients with 
cerebrovascular ischemic events being on aspirin for secondary stroke prophylaxis, non-
responsiveness was significantly associated with recurrent ischemia.6 
Peripheral arterial disease (PAD), in particular of the lower limbs, is highly prevalent 
especially in the elderly population.7 Its utmost importance as a marker of atherosclerotic 
vascular disease in general has been confirmed.8  
Percutaneous transluminal angioplasty (PTA) to revascularize peripheral arteries is an 
established treatment in symptomatic patients. Aspirin is given routinely to patients being 
treated for peripheral arterial disease and has been shown to reduce the risk of reocclusion 
after vascular procedures.9 Therefore, response to aspirin in this setting is of great importance.   
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A previous study analyzing the time course of agonist-induced platelet aggregation in patients 
who underwent PTA of the lower limbs provided inconclusive results and was only limited to 
a 12 months’ follow-up.10 
Here, we wanted to investigate if, apart from the known variable interindividual platelet 
response to aspirin, an intraindividual variability also exists, and, if so, whether such an 
intraindividual variance has a consequence for clinical outcome. To this end, individual 
variances were correlated first with the occurrence of restenosis/reocclusion in patients after 
PTA of the lower limbs within one year. Secondly, we tested the hypothesis that defined 
clinical endpoints (e.g. cardiovascular events such as myocardial infarction, stroke, peripheral 
re-intervention) during long-term follow up of up to almost eight years are more often reached 
in patients with a high variance.
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Materials and methods 
Patients  
The current study was done as a substudy of a previously published trial.11 Over a three-year-
period (January 1999 until December 2001) 109 of 250 patients screened patients with 
symptomatic (Fontaine clinical stage II-IV) PAD of the lower limbs, scheduled to undergo 
PTA at the Clinic of Angiology, University Hospital Zurich, were enrolled. The study was 
approved by the local ethics committee and performed according to the Declaration of 
Helsinki. All patients gave their written informed consent. Age, sex, cardiovascular risk 
factors, history and current medication were recorded at baseline. Characteristics of the 
lesions were recorded and classified according to the TransAtlantic interSocietal Consensus 
(TASC) classification.12 Basic treatment was 100mg aspirin daily which was initiated the day 
before the procedure if the patient was not already on aspirin (which was the case in all but 
two patients). Adjunctive drug therapy during the intervention (unfractionated or low-
molecular-weight heparin) was at the operator’s discretion. Patients were excluded if they 
were taking anticoagulants at the time of admission, had an intolerance to aspirin, active 
bleeding or hemorrhagic diathesis. Patients receiving non-steroidal anti-inflammatory agents 
(NSAID) were also excluded. Furthermore, patients with renal failure, uncontrolled arterial 
hypertension, recent surgery of the central nervous system, nonatherosclerotic vascular 
disease, lesions in femoropopliteal bypass grafts, stent implantation and stroke, were 
excluded, too. At time of admission, routine laboratory tests (complete blood cell count, 
hematocrit, serum creatinine, INR, cholesterol, triglycerides) were performed using standard 
methods.  
Mean follow-up was 80 months (range 52-94 months). Owing to the parallel group design of 
the original trial,11 patients had initially been randomized to one of two treatment arms (no 
additional treatment versus dalteparin, 5000 IU subcutaneously once daily on day 1 and 2 
after the intervention followed by 2500 IU once daily for 90 days in addition to aspirin 100 
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mg daily). Unpaired t-test revealed that, after three months, neither for ADP (p = 0.4942, ns), 
nor for epinephrine (p = 0.9594, ns) or collagen (p = 0.5541, ns) any significance of an 
influence of dalteparin on parameters of platelet aggregation could be observed. Therefore, 
patients that had received dalteparin within the first three months after angioplasty were also 
included into the current study.  
 
Follow-up and end points 
ADP-, collagen-, and epinephrin- induced platelet aggregation was assessed before, and at 1, 
3, 6, and 12 months after the percutaneous procedure. Patients were followed-up for 80 
months (range 52-94 months). The day after the procedure as well as at 1, 3, 6, and 12 months 
after PTA, all patients were examined clinically, and pulse volume recordings, determination 
of ankle brachial index (ABI), as well as colour-coded duplex sonography were performed. 
Furthermore, drug use, in particular NSAID and/or the addition of a thienopyridine, was 
monitored at the time of out-patient testing. Testing of platelet function was always performed 
under fasting conditions at the same time of the day (early in the morning). Long-term follow-
up was based on patient chart review in the majority of the cases. If this was not available, a 
telephone interview was performed.  
Outcome measures were the primary endpoint of restenosis/reocclusion in the dilated segment 
within one year and the secondary (combined) endpoint consisting of one or more of the 
following clinical endpoints during long-term follow-up: occurrence of a non-fatal 
cardiovascular event (myocardial infarction, stroke); death for cardiovascular cause; need for 
an invasive (either surgically or catheter-based) vascular intervention in any peripheral artery; 
worsening of clinical symptoms as documented by a drop in ABI of > 0.1. 
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Testing of platelet function 
ADP-, collagen-, and epinephrin- induced platelet aggregation were assessed by light 
transmittance aggregometry (LTA). In the fasting and resting patient, blood was taken from 
an antecubital vein via i. v. cannula (1.2 mm) directly into silicon-coated vacutainer tubes 
containing 0.5 ml buffered sodium citrate (3.8 %). Samples were processed immediately, and 
platelet aggregation was measured after centrifugation (100 G, 10 min, room temperature) of 
citrated blood (3.8%; 1:10) to get platelet-rich plasma (PRP). In addition, the remaining 
sample was further centrifuged at a higher rate (3000 G, 15 min, RT) to obtain platelet pure 
plasma (PPP). To determine platelet aggregation to the different agonists, a standardized 
plasma sample with a total platelet count of 250 G/ l was used by adjusting PRP with PPP. 
Platelets were stimulated with epinephrine (final concentration 0.1 mmol/l), collagen (final 
concentration 5 mg/l) and ADP (final concentration 0.002 mol/l), and aggregation was 
measured using an APACT 4 aggregometer (Ahrensburg, Germany). Aggregation was 
expressed as the maximum percentage change in light transmittance from baseline. 
The coefficient of variation (CV) for LTA in our laboratory was 8.9% (n=20). 
 
Statistical analysis 
For data management and analysis the statistical software package R, version 2.6.1 (R 
Development Core Team, Vienna, Austria) was used. Continuous variables are reported as 
means ± SD, categoric variables as counts and percentages. Pearson’s correlation was used to 
check if two continuous variables were strongly correlated, so that they could be treated as 
exchangeable. The Mann Whitney U test was used for comparisons of continuous variables, 
the chi-squared test for comparisons of categorical variables. A p value < 0.05 was considered 
to be statistically significant. 
Univariate mixture models: For each timepoint and each of the three measures (ADP, 
collagen, epinephrine) we first fit three different univariate models: one using the ordinary 
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normal distribution, one using a mixture of two normal distributions with equal variances and 
one using a mixture of two completely distinct normal distributions. The different models 
were calculated using an expectation-maximization (EM) algorithm. They were compared 
graphically and via the Akaike’s information criterion (AIC). The model with the smallest 
AIC for each timepoint has been selected. 
Box-Cox-transformation: To compare variances of ADP-, collagen-, or epinephrine-induced 
platelet aggregation over time between patients with and without restenosis and between  
patients reaching one of the endpoints and those who did not, a t-test can only be performed if 
these variances are approximately normally distributed in both groups. As this was not the 
case, we used the Box-Cox transformation to achieve normality. We decided to use the 
quartic root (i.e. the squareroot of the standard deviation) of the variances of ADP, collagen, 
and epinephrine. Furthermore, in order to appropriately incorporate the fact of variable 
numbers of measurements in different individuals into the analyses, a weighted t-test was 
used. To avoid the problem of multiple testing, Bonferroni correction was used. 
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Results 
Baseline demographic and clinical characteristics as well as laboratory variables are shown in  
Table 1A and 1B.  
Patients were grouped according to the occurrence of restenosis/reocclusion within 12 months 
(table 1A) as the primary endpoint and according to the occurrence of any fatal or non-fatal 
cardiovascular event and/ or the need for any surgically or catheter-based vascular 
intervention (i.e. secondary endpoint) during complete long-term follow-up (table 1B). As 
expected, patients with restenosis/reocclusion had a lower ankle-brachial index than those 
without restenosis/reocclusion within the first year (0.64±0.17 vs. 0.74±0.19; p=0.0077) 
(table 1A). Patients reaching the combined endpoint were slightly younger than those who 
did not (68±11 years vs. 72±10 years; p=0.046) (table 1B). Apart from these differences, the 
groups were similar with respect to their baseline parameters.   
Mean values of ADP-, epinephrine- and collagen-induced platelet aggregation, as assessed by 
LTA, for all patients up to one year after the initial percutaneous procedure are shown in 
Table 2. 
When comparing these values between patients with any event and those without during long-
term follow-up, no significant differences could be detected.  
Only 25.6% of the patients were sampled at 12 months, and 52 % of all patients had their 
agonist-induced platelet aggregation measured at ≥ three timepoints (table 2). However, in 
order to circumvene this problem, and to analyze individual variances in the best possible way 
under these circumstances, a weighted t-test was performed.  
We then wanted to investigate if subgroups exist, i.e. patients whose values for platelet 
aggregation upon stimulation are at all timepoints higher or lower than the average. To this 
end, we first plotted all data separately for each individual. 
      Figure 1. 
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There was a considerable amount of variation in most of the individuals. As outlined above, 
we therefore tried to fit mixture distributions in the univariate (i. e. for all timepoints 
separately) case. For each timepoint we chose for ADP (epinephrine and collagen not shown) 
the best out of three possible univariate models (normal distribution; mixture of two normal 
distributions with equal variances; mixture of two distinct normal distributions). A mixture of 
two normal distributions with distinct variances was chosen for time points 0 and 12. A 
mixture of two normal distributions with equal variance was chosen for timepoints 3 and 6. 
One normal distribution was chosen for timepoint 1. 
       Figure 2. 
We found there was no distinct subgroup detectable which would remain the same over the 
observed time period.   
We also calculated correlations of the agonists ADP, epinephrine and collagen for all five 
timepoints. Although there was a positive correlation remaining relatively constant over time, 
this correlation is not strong (between r=0.25 and r=0.64). Therefore, we did not treat the 
agonists as exchangeable.   
We then wanted to analyze whether the initially observed high variance of ADP-, 
epinephrine-, and collagen- induced platelet aggregation within any individual patient might 
have a significant influence on the occurrence of restenosis/reocclusion (within one year after 
PTA) and/ or the combined endpoint (during complete long-term follow-up). Results of a 
weighted t-test are shown in 
      Table 3. 
In all but one constellation there was no evidence for a difference between the groups. Only 
for the time course of collagen, a p-value below 0.05 indicated a significant difference with 
respect to the occurrence of restenosis/reocclusion. However, in this context, the multiple 
testing problem has to be borne in mind, so that the probability of a wrong significant result 
cannot be controlled via  α = 0.05 any more. The appropriate level of significance resulting 
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from the Bonferroni correction is 0.008. Therefore, no evidence for a difference between the 
groups could be found. 
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Discussion 
In our study with its unique aspects of multiple time points of platelet function testing and a 
very long clinical follow-up we found that platelet aggregation results using light transmission 
aggregometry in symptomatic patients with PAD intraindividually vary considerably over 
time and do not correlate with long-term outcome. To the best of our knowledge, this is the 
first study to describe this. Others have recently reported a high intra-individual variability of 
ADP- and collagen- induced platelet aggregation.13 However, these findings were observed in 
healthy individuals receiving aspirin for up to eight weeks only whereas we describe this for 
the first time in a pathophysiologic context. Furthermore, we had multiple time points for 
platelet function testing during a long period of twelve months and correlated our findings 
with clinical endpoints during a follow-up of up to eight years. 
Because of the missing values especially for the later timepoints, it was difficult to fit 
complex mixture distributions. However, we could circumvene this problem by using a 
weighted t-test. We cannot rule out that variable numbers of measurements in different 
individuals might possibly have affected our data on the correlation between intraindividual 
variance and long term cardiovascular outcome. However, our main conclusion (i.e. that 
testing of platelet function at one timepoint only has reduced significance) remains 
unaffected.  
This finding may potentially entail serious implications, as it means that on-treatment function 
testing of aspirin, done at one timepoint, usually before a peripheral or coronary intervention 
in certain patients at individually high risk for thrombosis, has a reduced significance, at least 
when LTA is used. This could also mean that a correlation between response to aspirin and 
clinical events (as shown in several studies in the past) has to be interpreted with caution.  
Low-dose daily aspirin is a widely accepted strategy for secondary prevention in patients with 
vascular disease. It is still a matter of controversy if the biochemical detection of hypo- or 
non-responsiveness to aspirin has a clinical meaning, i. e. an association with thrombotic 
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events. However, in our study we could not show that the individually high variance translates 
into a higher risk for restenosis/reocclusion after PTA or for the occurrence of a major 
cardiovascular event.  
We further found no obvious hint for the existence of subgroups of patients in which platelet 
aggregation testing revealed a lack of response to aspirin at all time points. With univariate 
mixture models fit to find the correct location for each individual within the mixture clearly 
separated patients could not be identified. 
An interesting hypothesis which arises from our work is that a single patient being a 
responder to aspirin once will not always be a responder.  
In this context, the different etiologies for “aspirin resistance” have to be borne in mind.  
One of the most important reasons for “aspirin resistance” is a lack of compliance.14, 15 
However, virtually all our patients had been on aspirin at the beginning of the study. The 
variation in platelet response to agonists as depicted in figure 1 would imply a high degree of 
irregularity in taking aspirin which makes this explanation completely speculative. In a 
previous study platelet hyporesponsiveness to aspirin was evaluated in 24 patients at day ten 
and one month after coronary artery bypass graft surgery.16 The authors found that although 
most patients could be classified as “aspirin-resistant” shortly after their operation, 
responsiveness to aspirin was restored in a majority of the patients at one month’ follow-up .16 
We used in the present work a completely different study design in a different group of 
patients. Furthermore, we here describe a high degree of individual variance in the platelet 
responsiveness to aspirin rather than a restoration of platelet function. However, our data also 
point to a transient nature of response to aspirin, implying its modifiability.  
In this study, we did not aim to identify possible modulating factors nor to tackle the question 
whether a defective action of aspirin on the arachidonic acid pathway, insufficient 
bioavailability, inadequate, i. e. too low dosage or a progression of peripheral artery disease 
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are causally involved.17, 18 However, none of the afore mentioned causes could really explain 
the phenomenon described here.  
Platelet alterations have previously been described in patients with peripheral arterial 
disease.19 Thus, it is conceivable that platelet-plaque interaction and/or platelet-injured 
endothelial cell interaction may modulate platelet function to a variable degree, depending on 
the actual state of disease, influenced by inflammatory processes. 
Strong evidence linking “aspirin resistance” assayed ex vivo and the future risk of myocardial 
infarction, stroke or cardiovascular death came from a nested case-control study on a 
subgroup of patients enrolled in the HOPE study.20 In the current study, it was not our 
principal aim to merely correlate response to aspirin with clinical long-term outcome.  
Interestingly, in a previous reproducibility study specifically designed to measure platelet 
aggregation over time, very consistent results were found in a small proportion of individuals 
exhibiting an unusual hyperreactivity to agonists.21 However, this study had been performed 
in healthy volunteers not being on aspirin.  
Our results cast doubt on the significance of platelet function testing using LTA in patients 
while being on aspirin when assessed at one timepoint only. Our data may imply that the 
modalities of such tests will have to be refined in the future. 
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Table 1: Baseline demographic and clinical characteristics of all patients by endpoints 
 
 
A 
        restenosis/  no restenosis/  p 
      reocclusion  reocclusion 
      (n= 48)  (n=61) 
 
Age (years)     68±11.3  70±10.2  0.377 
Male      25 (52%)  36 (59%)  0.353 
Diabetes     16 (33%)  18 (30%)  0.755 
Hypercholesterolemia   35 (73%)  41 (67%)  0.565 
Arterial Hypertension    37 (77%)  50 (82%)  0.439 
Pack years     32.98±29.1  34.33±40.0  0.848 
History of coronary heart disease  16 (33%)  26 (43%)  0.258 
History of cerebrovascular disease  8 (17%)  6 (10%)  0.322 
TASC classification          0.207 
 A     9 (19%)  12 (20%)  
 B     10 (21%)  22 (36%) 
 C     21 (44%)  22 (36%) 
 D     8 (17%)  5 (8%) 
Ankle-brachial index    0.64±0.17  0.74±0.19           0.0077 
Platelet count (x103/µl)   256±73  265±75  0.544 
Fibrinogen (mg/dl)    396±97  381±79  0.401 
 
 
 
B 
        with events*  without events* p 
      (n=66)   (n=43) 
 
Age (years)     68.1±11.4  72.3±9.7  0.046 
Male      37 (56%)  24 (56%)  0.979 
Diabetes     23 (35%)  11 (26%)  0.307 
Hypercholesterolemia   50 (76%)  27 (63%)  0.146 
Arterial Hypertension    51 (77%)  37 (86%)  0.256 
Pack years     36.4±38.8  27.9±28.2  0.234 
History of coronary heart disease  24 (36%)  18 (42%)  0.564 
History of cerebrovascular disease  11 (1.5%)  3 (7%)   0.139 
TASC classification          0.722
 A     11 (17%)  10 (23%)  
 B     19 (29%)  13 (30%)  
 C     26 (39%)  16 (37%)  
 D     10 (15%)  4 (9%)   
Ankle-brachial index    0.68±0.19  0.71±0.19  0.514 
Platelet count (x103/µl)   270±78  249±66  0.156 
Fibrinogen (mg/dl)    392±94  386±80  0.740 
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*events = clinical endpoints (myocardial infarction, stroke, peripheral re-intervention at any 
site; death for cardiovascular cause) 
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Table 2: ADP-, epinephrine- and collagen- induced platelet aggregation according to the 
secondary endpoint in PAD patients (n=109) on aspirin before and during a follow-up 
period of twelve months after PTA. 
Values are means ± SD, in %. 
 
 
 
 
 with events* (n=66) without events* (n=43) p 
ADP    
Baseline (n=109) 35.2 ±15.1 34.6±15.0 0.839 
1 month (n=57) 32.4±12.7 33.5±15.4 0.777 
3 months (n=39) 31.7±14.4 31.9±17.1 0.964 
6 months (n=28) 38.2±19.6 35.7±9.4 0.716 
12 months (n=28) 35.9±11.9 32.6±12.0 0.480 
 
 
Epinephrine    
Baseline (n=108)  42.1±18.5 43.6±20.3 0.701 
1 month (n=57) 41.0±20.6 41.8±16.5 0.879 
3 months (n=38) 40.0±18.8 34.7±18.3 0.382 
6 months (n=28) 41.2±19.3 41.6±14.9 0.963 
12 months (n=24) 43.0±24.1 34.8±13.4 0.342 
 
 
Collagen    
Baseline (n=108) 45.0±20.4 48.8±21.2 0.357 
1 month (n=55) 45.6±18.3 52.8±18.7 0.176 
3 months (n=38) 50.3±13.9 42.5±15.0 0.103 
6 months (n=28) 50.3±21.9 48.2±16.6 0.802 
12 months (n=22) 48.3±24.6 48.0±21.3 0.976 
 
*events = clinical endpoints (myocardial infarction, stroke, peripheral re-intervention at any 
site; death for cardiovascular cause) 
 
 22 
Table 3: Point estimates, confidence intervals and p-values for a weighted t-test for 
differences of the quartic root of the variances for ADP-, epinephrine- and collagen- 
induced platelet aggregation. Restenosis indicates restenosis/reocclusion of the dilated 
segment within one year, event indicates the secondary (=combined) endpoint during 
long-term follow-up. 
 
 
 
 
 point estimate Lower limit upper limit p 
ADP, restenosis/ 
reocclusion 
-0.087 -0.632 0.458 0.751 
ADP, event* 0.011 -0.520 0.542 0.967 
     
COLL, restenosis/ 
reocclusion 
-0.551 -1.035 -0.067 0.026 
COLL, event* -0.116 -0.613 0.380 0.643 
     
EPI, restenosis/ 
reocclusion 
0.129 -0.365 0.622 0.605 
EPI, event* 0.411 -0.067 0.889 0.091 
 
 
*event = clinical endpoints (myocardial infarction, stroke, peripheral re-intervention at any 
site; death for cardiovascular cause) 
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Legends to figures 
Figure 1: Platelet aggregation to ADP, collagen and epinephrine separately for each 
individual at five different timepoints (n=109). There are variable numbers of measurements 
per individual. 
Figure 2: Distribution of values for ADP-induced platelet aggregation over time.  
0 indicates baseline, 1, 3, 6, and 12 indicate months of follow-up. For each timepoint, the best 
of three possible fitting models (mixture of two completely distinct normal distributions; 
mixture of two normal distributions with equal variances; model with just one normal 
distribution) was chosen. For a detailed description see Methods. 
  
 
 
 
 
 
 
 
 
 
